Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 1998
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study
P Hoskins, E Eisenhauer, S Beare, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2000
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study
P Hoskins, E Eisenhauer, I Vergote, et al.
Cancer Research
|
August 14, 1999
Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
S R Johnston, I M Boeddinghaus, S Riddler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J J Biagi, A M Oza, H I Chalchal, et al.
Genome Biology and Evolution
|
June 20, 2019
Simultaneous TE Analysis of 19 Heliconiine Butterflies Yields Novel Insights into Rapid TE-Based Genome Diversification and Multiple SINE Births and Deaths
David A Ray, Jenna R Grimshaw, Michaela K Halsey, et al.
Journal of the National Cancer Institute
|
October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
P Hoskins, I Vergote, A Cervantes, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2004
A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
S R D Johnston, L A Gumbrell, T R J Evans, et al.
Science (New York, N.Y.)
|
April 27, 2023
Insights into mammalian TE diversity through the curation of 248 genome assemblies
Austin B Osmanski, Nicole S Paulat, Jenny Korstian, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
M J Piccart, K Bertelsen, G Stuart, et al.
Journal of the National Cancer Institute
|
May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
M J Piccart, K Bertelsen, K James, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 1998
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study
P Hoskins, E Eisenhauer, S Beare, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2000
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study
P Hoskins, E Eisenhauer, I Vergote, et al.
Cancer Research
|
August 14, 1999
Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
S R Johnston, I M Boeddinghaus, S Riddler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J J Biagi, A M Oza, H I Chalchal, et al.
Genome Biology and Evolution
|
June 20, 2019
Simultaneous TE Analysis of 19 Heliconiine Butterflies Yields Novel Insights into Rapid TE-Based Genome Diversification and Multiple SINE Births and Deaths
David A Ray, Jenna R Grimshaw, Michaela K Halsey, et al.
Journal of the National Cancer Institute
|
October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
P Hoskins, I Vergote, A Cervantes, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2004
A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
S R D Johnston, L A Gumbrell, T R J Evans, et al.
Science (New York, N.Y.)
|
April 27, 2023
Insights into mammalian TE diversity through the curation of 248 genome assemblies
Austin B Osmanski, Nicole S Paulat, Jenny Korstian, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
M J Piccart, K Bertelsen, G Stuart, et al.
Journal of the National Cancer Institute
|
May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
M J Piccart, K Bertelsen, K James, et al.
Page
of 4